Short answer · Medically reviewed summary · Last updated: 2026-04-07
Glanzmann’s thrombasthenia was first identified in 1918 by Swiss pediatrician Eduard Glanzmann, who described a hereditary bleeding disorder characterized by normal platelet counts but impaired platelet function. Over the past century, our understanding of Glanzmann’s thrombasthenia has shifted from a clinical observation of "bleeding diathesis" to a precise molecular diagnosis involving defects in the ITGA2B or ITGB3 genes, which encode the integrin αIIbβ3 receptor required for platelet aggregation. Who first discovered Glanzmann’s thrombasthenia? The history of Glanzmann’s thrombasthenia begins in 1918, when Eduard Glanzmann, a Swiss pediatrician, published his observations on several children who suffered from severe mucosal bleeding.
What is the history of Glanzmanns thrombasthenia?
History of Glanzmanns thrombasthenia: when and how it was discovered, and the milestones in research since, medically reviewed.
Glanzmann’s thrombasthenia was first identified in 1918 by Swiss pediatrician Eduard Glanzmann, who described a hereditary bleeding disorder characterized by normal platelet counts but impaired platelet function. Over the past century, our understanding of Glanzmann’s thrombasthenia has shifted from a clinical observation of "bleeding diathesis" to a precise molecular diagnosis involving defects in the ITGA2B or ITGB3 genes, which encode the integrin αIIbβ3 receptor required for platelet aggregation.
Who first discovered Glanzmann’s thrombasthenia?
The history of Glanzmann’s thrombasthenia begins in 1918, when Eduard Glanzmann, a Swiss pediatrician, published his observations on several children who suffered from severe mucosal bleeding. At the time, he termed the condition "hereditary hemorrhagic thrombasthenia." Glanzmann noted that while the children’s blood contained a normal number of platelets, these platelets failed to retract the blood clot properly, a hallmark clinical sign that differentiates Glanzmann’s thrombasthenia from other thrombocytopenic purpuras.
How has our understanding of the condition evolved?
For decades following its discovery, Glanzmann’s thrombasthenia was defined primarily by the failure of platelets to aggregate in response to standard agonists like ADP, epinephrine, or thrombin. It was not until the 1960s and 1970s that researchers identified the specific culprit: the absence or dysfunction of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex on the surface of platelets. This discovery revolutionized the field, moving the diagnosis from purely functional clot-retraction tests to the identification of specific protein deficiencies using flow cytometry.
What are the major milestones in the study of Glanzmann’s thrombasthenia?
The evolution of knowledge regarding Glanzmann’s thrombasthenia has been marked by several significant scientific breakthroughs:
- 1918: Eduard Glanzmann provides the first clinical description of the disorder.
- 1970s: Identification of the GPIIb/IIIa complex deficiency as the primary biochemical defect.
- 1990s: The advent of molecular genetics allows for the identification of mutations in the ITGA2B and ITGB3 genes, confirming the autosomal recessive inheritance pattern.
- Modern Era: Development of recombinant Factor VIIa as a targeted therapy for patients who develop antibodies (alloimmunization) after frequent platelet transfusions.
How did genetics change the diagnosis of Glanzmann’s thrombasthenia?
Before the molecular era, patients were often misdiagnosed or grouped under broad categories of "platelet function disorders." The ability to sequence the ITGA2B and ITGB3 genes has allowed clinical geneticists to confirm diagnoses definitively, which is crucial for family planning and carrier identification. Today, with 59 people with Glanzmann’s thrombasthenia documented in the DiseaseMaps community, we see how global connectivity has helped patients share their diverse experiences with these genetic variations, moving the focus from historical misconceptions—such as the idea that all platelet bleeding was caused by low counts—to personalized management strategies.
Next steps
- Consult a hematologist specializing in rare bleeding disorders to discuss the latest management options.
- Reach out to the 59 members of the DiseaseMaps community to share experiences and coping strategies.
- Ask your physician about genetic counseling if you are considering family planning.
- Maintain a detailed "bleeding diary" to help your medical team track your response to treatments like antifibrinolytics or recombinant Factor VIIa.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider.
References
- Orphanet: Glanzmann thrombasthenia (ORPHA:3326).
- NIH Genetic and Rare Diseases Information Center (GARD): Glanzmann thrombasthenia.
- OMIM (Online Mendelian Inheritance in Man): Thrombasthenia of Glanzmann and Naegeli (#273800).
- National Hemophilia Foundation: Information on rare bleeding disorders.
